The BAHEAL Intelligent Technology and Philips reached a strategic cooperation - Provide personalized and precision medical services based on artificial intelligence to the patients through the cloud-based interconnection
Release Time:2017-11-17 View Count:1040

On November 17, 2017, the Qingdao BAHEAL Intelligent Technology Co. Ltd. subordinate to the BAHEAL Pharmaceutical Group and Philips (China) Investment Co., Ltd. held a signing ceremony at the headquarter of the Philips Greater China. Li Qin, CEO of the BAHEAL Intelligent Technology, and Liang Jianqiu, the general manager of Strategy & Business Development of Philips Greater China signed the contract on behalf of both parties. Representatives of both parties including President Fu Gang of the BAHEAL Pharmaceutical Group and He Guowei, the CEO of Philips Greater China also attended the signing ceremony. The two companies will work hard to play their respective technological and resource advantages to explore innovative business models for precision medical solutions based on artificial intelligence starting from the field of ontology and provide personalized medical services to patients by providing decision support to doctors.

BAHEAL Intelligent Technology and Philips formally signed the contract

Based on the strategic cooperation memorandum, the first step of the cooperation of both parties is to explore the innovative business mode based on the mature patient education, brand operation capability and strong marketing network of the BAHEAL Pharmaceutical Group starting from the field of oncology and enable that the Nebula Workstation, an imaging-assisted diagnostic system based on artificial intelligence technology by the Philips, can provide decision support to physicians through the cloud interconnection and directly provide personalized precise diagnosis services to patients so that patients can have a more transparent and objective understanding of the diagnosis process and their own conditions, thereby enhancing the autonomy of patients in personal health management.

The cooperation between the two parties will start from the field of lung cancer that has witnessed the fastest increase in morbidity and mortality in China and is one of the biggest threaten to the life and health of the population. The vast majority of lung cancer patients are already in the stage of metastasis and diffusion of the tumors when they are identified, so early screening and diagnosis of lung cancer are of crucial importance. As the early screening and precise diagnosis of pulmonary nodules are conducive to positive intervention and can effectively prevent the occurrence and development of lung cancer. The two companies plan to automatically identify pulmonary nodules by means of intelligent imaging during the physical examination for healthy people, provide doctors with diagnostic decision support and make the patients understand their condition through easy-to-understand imaging diagnosis reports so as to provide a reference for further treatment, and thus greatly reducing the incidence of missed diagnosis of pulmonary nodules in healthy population. Both parties intend to gradually extend this model to other clinical diseases.

He Guowei, the CEO of Philips Greater China, said that "Artificial Intelligence is an important part of Philips' strategy. According to our expectation, most of Philips products will be based on artificial intelligence technology in the future. We grasp the trend of the integration of personal health consumption and professional medical services and devote to helping medical staff to make faster and better diagnosis, improving the efficiency and effectiveness and managing and serving more patients through effective remote means with the innovative achievements based on artificial intelligence technology and clinical experience; At the same time, we strive to provide consumers and patients with more convenient and efficient health and medical services at a lower cost. The 'Intelligence + Health' service model of the "Three-End, Two-Cloud and One-Platform" by the BAHEAL Intelligent Technology has exploited an innovative business model for the imaging-assisted diagnostic system based on artificial intelligence technology by the Philips, enables it to play a more a broader and universal role in early screening of such diseases as lung cancer, benefit more doctors and patients and help patients better achieve self-management of medical services and be aware that whether the acquired medical service is effective and valuable instead of being 'consumed' through providing doctors with decision support,.

President Fu Gang of the BAHEAL Pharmaceutical Group said that “the BAHEAL Pharmaceutical Group is a pharmaceutical company driven by intelligent information technology with excellent medical industry integration capabilities. It has 1,200 dealers, 12,000 hospitals and 230,000 pharmacies in China; At the same time, the new type of medical informatization including artificial intelligence is the core of the development direction of the BAHEAL Pharmaceutical Group, and medical information solutions have been provided to many medical institutions in various provinces and cities in China.

In this cooperation with Philips to explore B2C promotion model of intelligent medical imaging field, we will quickly push the imaging-assisted diagnostic system based on artificial intelligence technology by the Philips to the market through the huge marketing network and sophisticated customer system of BAHEAL and rapidly benefit doctors and patients. There are 4.3 million new patients with cancer each year in China, and the five-year survival rate is only 37% while that of the United States is 67%. The imperfect prevention system of physical examination in China is an important reason. We hope that, through the cooperation with the world's top health technology company such as the Philips and the increase in the R & D investment in early warning and screening of cancer, we can provide intelligent support for the decision-making of doctors in the early cancer screening, realize early detection and standardized treatment of cancer patients, improve the chances of survival of patients."

In addition, the two parties also intend to work together to build the first independent imaging center based on big data and artificial intelligence technologies in Qingdao, Shandong Province. Upon the completion, the center will rely on the imaging-assisted diagnostic system based on artificial intelligence technology by the Philips and interconnect with the medical institutions, physical examination centers and nursing homes at all levels through the cloud to provide imaging diagnosis services to help doctors improve diagnostic speed and accuracy, and thus achieving the homogenization of medical level and reducing the rate of misdiagnosis and missed diagnosis rate. Both parties will give full play to their respective resource advantages and continuously improve the service quality, service depth and service accessibility of the center.


Share:
Back to Top